Novocure outlines $690M-$710M 2026 revenue guidance as Optune Pax launch reaches 169 prescriptions in 7 weeks
Source: SeekingAlpha
2026-04-30 14:44:21 ET
More on NovoCure
- NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript
- NovoCure Limited 2026 Q1 - Results - Earnings Call Presentation
- NovoCure Limited 2025 Q4 - Results - Earnings Call Presentation
- Novocure jumps after raising FY26 sales outlook, Q1 revenue beat
- NovoCure reports mixed Q1 results; updates FY26 outlook
Read the full article on Seeking Alpha
For further details see:
Novocure outlines $690M-$710M 2026 revenue guidance as Optune Pax launch reaches 169 prescriptions in 7 weeks
NovoCure Limited
NASDAQ: NVCR
NVCR Trading
28.92% G/L:
$15.20 Last:
3,202,896 Volume:
$13.36 Open:
NVCR Latest News
NVCR Stock Data
$1,170,211,701
105,800,576
0.07%
77
N/A
Medical Equipment & Supplies
Healthcare
JE
St. Helier
